These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31239053)

  • 1. Design of RNA-targeting macrocyclic peptides.
    Walker MJ; Varani G
    Methods Enzymol; 2019; 623():339-372. PubMed ID: 31239053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptides and peptidomimetics as inhibitors of protein-protein interactions involving β-sheet secondary structures.
    Laxio Arenas J; Kaffy J; Ongeri S
    Curr Opin Chem Biol; 2019 Oct; 52():157-167. PubMed ID: 31590141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAR-RNA recognition by a novel cyclic aminoglycoside analogue.
    Raghunathan D; Sánchez-Pedregal VM; Junker J; Schwiegk C; Kalesse M; Kirschning A; Carlomagno T
    Nucleic Acids Res; 2006; 34(12):3599-608. PubMed ID: 16855296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motif mediated protein-protein interactions as drug targets.
    Corbi-Verge C; Kim PM
    Cell Commun Signal; 2016 Mar; 14():8. PubMed ID: 26936767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational modulator design by exploitation of protein-protein complex structures.
    Wichapong K; Poelman H; Ercig B; Hrdinova J; Liu X; Lutgens E; Nicolaes GA
    Future Med Chem; 2019 May; 11(9):1015-1033. PubMed ID: 31141413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction.
    Zhou H; Liu L; Huang J; Bernard D; Karatas H; Navarro A; Lei M; Wang S
    J Med Chem; 2013 Feb; 56(3):1113-23. PubMed ID: 23244744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antimicrobial activity against Pseudomonas aeruginosa of macrocyclic β-hairpin peptidomimetic antibiotics containing N-methylated amino acids.
    Vetterli SU; Moehle K; Robinson JA
    Bioorg Med Chem; 2016 Dec; 24(24):6332-6339. PubMed ID: 27240465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuating HIV Tat/TAR-mediated protein expression by exploring the side chain length of positively charged residues.
    Wu CH; Chen YP; Liu SL; Chien FC; Mou CY; Cheng RP
    Org Biomol Chem; 2015 Dec; 13(45):11096-104. PubMed ID: 26399751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-hairpin peptidomimetics: design, structures and biological activities.
    Robinson JA
    Acc Chem Res; 2008 Oct; 41(10):1278-88. PubMed ID: 18412373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design-Based Peptidomimetic Ligand Discovery to Target HIV TAR RNA Using Comparative Analysis of Different Docking Methods.
    Fu J; Xia A; Dai Y; Qi X
    Curr HIV Res; 2016; 14(6):476-483. PubMed ID: 27450546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.
    Karatas H; Li Y; Liu L; Ji J; Lee S; Chen Y; Yang J; Huang L; Bernard D; Xu J; Townsend EC; Cao F; Ran X; Li X; Wen B; Sun D; Stuckey JA; Lei M; Dou Y; Wang S
    J Med Chem; 2017 Jun; 60(12):4818-4839. PubMed ID: 28603984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic combinatorial chemistry as a rapid method for discovering sequence-selective RNA-binding compounds.
    McAnany JD; Miller BL
    Methods Enzymol; 2019; 623():67-84. PubMed ID: 31239058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 drug discovery: targeting folded RNA structures with branched peptides.
    Wynn JE; Santos WL
    Org Biomol Chem; 2015 Jun; 13(21):5848-58. PubMed ID: 25958855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Targeting the HIV-1 Tat/TAR Complex.
    Abulwerdi FA; Le Grice SFJ
    Curr Pharm Des; 2017; 23(28):4112-4121. PubMed ID: 28625133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptides and peptidomimetics as regulators of protein-protein interactions.
    Cunningham AD; Qvit N; Mochly-Rosen D
    Curr Opin Struct Biol; 2017 Jun; 44():59-66. PubMed ID: 28063303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges.
    Sawyer TK; Partridge AW; Kaan HYK; Juang YC; Lim S; Johannes C; Yuen TY; Verma C; Kannan S; Aronica P; Tan YS; Sherborne B; Ha S; Hochman J; Chen S; Surdi L; Peier A; Sauvagnat B; Dandliker PJ; Brown CJ; Ng S; Ferrer F; Lane DP
    Bioorg Med Chem; 2018 Jun; 26(10):2807-2815. PubMed ID: 29598901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mechanistic study on the inhibition of α-chymotrypsin by a macrocyclic peptidomimetic aldehyde.
    Zhang X; Bruning JB; George JH; Abell AD
    Org Biomol Chem; 2016 Aug; 14(29):6970-8. PubMed ID: 27349772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA as a target for drug design, the example of Tat-TAR interaction.
    Froeyen M; Herdewijn P
    Curr Top Med Chem; 2002 Oct; 2(10):1123-45. PubMed ID: 12173971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designed Macrocyclic Peptides as Nanomolar Amyloid Inhibitors Based on Minimal Recognition Elements.
    Spanopoulou A; Heidrich L; Chen HR; Frost C; Hrle D; Malideli E; Hille K; Grammatikopoulos A; Bernhagen J; Zacharias M; Rammes G; Kapurniotu A
    Angew Chem Int Ed Engl; 2018 Oct; 57(44):14503-14508. PubMed ID: 29908130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discoveries of Tat-TAR interaction inhibitors for HIV-1.
    Yang M
    Curr Drug Targets Infect Disord; 2005 Dec; 5(4):433-44. PubMed ID: 16535863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.